These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33437717)

  • 1. Interim value set for the EQ-5D-5L in Iran using the Crosswalk method.
    Ameri H; Safari H; Yousefi M; Bagheri Faradonbeh S; Goudarzi R; Soofi M
    Med J Islam Repub Iran; 2020; 34():121. PubMed ID: 33437717
    [No Abstract]   [Full Text] [Related]  

  • 2. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
    Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
    Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosswalk EQ-5D-5L Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M
    Zdr Varst; 2020 Sep; 59(3):189-194. PubMed ID: 32952720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
    Kularatna S; Chen G; Byrnes J; Scuffham PA
    Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.
    van Hout B; Janssen MF; Feng YS; Kohlmann T; Busschbach J; Golicki D; Lloyd A; Scalone L; Kind P; Pickard AS
    Value Health; 2012; 15(5):708-15. PubMed ID: 22867780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets.
    Jiang R; Rand K; Kuharic M; Pickard AS
    Health Qual Life Outcomes; 2022 Sep; 20(1):134. PubMed ID: 36085228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the properties of the EQ-5D-5L and EQ-5D-3L in general population in Iran.
    Rezaei S; Woldemichael A; Ahmadi S; Mohamadi Bolbanabad A; Zahir Abdullah F; Piroozi B
    Int J Health Plann Manage; 2021 Sep; 36(5):1613-1625. PubMed ID: 34013594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EQ-5D-5L is More Discriminative Than the EQ-5D-3L in Patients with Diabetes in Singapore.
    Wang P; Luo N; Tai ES; Thumboo J
    Value Health Reg Issues; 2016 May; 9():57-62. PubMed ID: 27881260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do EQ-5D-3L and EQ-5D-5L compare in a Swedish total hip replacement population?
    Eneqvist T; Nemes S; Kärrholm J; Burström K; Rolfson O
    Acta Orthop; 2020 Jun; 91(3):272-278. PubMed ID: 32237930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.
    Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N
    Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.
    Pan CW; Sun HP; Wang X; Ma Q; Xu Y; Luo N; Wang P
    Qual Life Res; 2015 Jul; 24(7):1767-74. PubMed ID: 25540029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EQ-5D-5L Polish population norms.
    Golicki D; Niewada M
    Arch Med Sci; 2017 Feb; 13(1):191-200. PubMed ID: 28144271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?
    Feng Y; Devlin N; Herdman M
    Health Qual Life Outcomes; 2015 Oct; 13():171. PubMed ID: 26489956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
    Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
    Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol.
    Bailey H; Roudijk B; Brathwaite R
    Eur J Health Econ; 2024 Jul; ():. PubMed ID: 38982011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosswalk algorithms for the conversion of mean EQ-5D indices calculated with different value sets.
    Nemes S; Garellick G; Salomonsson R; Rolfson O
    Scand J Public Health; 2016 Jul; 44(5):455-61. PubMed ID: 27090196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.